Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT04685317

Safety and Efficacy of the Sentinel Cerebral Protection Device in Atrial Fibrillation Ablation

Led by Malini Madhavan · Updated on 2025-06-11

48

Participants Needed

1

Research Sites

195 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of the study is to see if the Sentinel® Cerebral Protection System may prevent occurrence of stroke during an ablation procedure for atrial fibrillation (AF). The secondary purpose of this study is to study if cognitive function after AF ablation differs between those treated with the Sentinel cerebral protection device and those who do not receive the device.

CONDITIONS

Official Title

Safety and Efficacy of the Sentinel Cerebral Protection Device in Atrial Fibrillation Ablation

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Men or women over age 18 undergoing radiofrequency, pulsed field, or cryo-balloon ablation for atrial fibrillation according to current guidelines
  • Patients with symptomatic paroxysmal, persistent, or long-standing persistent AF not responsive or intolerant to Class I or III anti-arrhythmic drugs, or before starting such drugs
  • Able to provide informed consent
  • Acceptable aortic arch anatomy and vessel size without significant narrowing as shown by pre-procedure CT angiogram
Not Eligible

You will not qualify if you...

  • Unsuitable anatomy for Sentinel device including compromised right extremity blood flow or severe tortuosity, stenosis (>70%), dissection, or aneurysm of brachiocephalic, left carotid, or aortic arch vessels
  • Stroke or transient ischemic attack within the past six months
  • Carotid disease needing treatment within six weeks
  • Unable or unwilling to provide informed consent
  • Pregnant women
  • Known dementia
  • Known allergy to nickel-titanium
  • Presence of MRI-incompatible implanted devices including cardiac electronic devices
  • Presence of left atrial thrombus confirmed by echocardiogram
  • Reversible cause of AF such as hyperthyroidism

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Mayo Clinic in Rochester

Rochester, Minnesota, United States, 55905

Actively Recruiting

Loading map...

Research Team

G

Grace Purkey

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Safety and Efficacy of the Sentinel Cerebral Protection Device in Atrial Fibrillation Ablation | DecenTrialz